MULTIFOCAL HPV DISEASE IMIQUIMOD AN ALTERNATIVE THERAPY Vitorino A, Ferreira S, Pinto Vieira L, Nabais H Fundação D. Anna Sommer Champalimaud Dr. Carlos.

Slides:



Advertisements
Similar presentations
PROF OF OB &GYN. AIN SHAMS UNIVERSITY,GYNEONCOLOGY UNIT.
Advertisements

Diagnosis & Management Of VAIN/VIN
CANCER OF THE VAGINA Dr Samar Sarsam
In the name of God Isfahan medical school Shahnaz Aram MD.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
Cervical Cancer. Dr. Swapna Chaudhary M.S. (MUM) Consultant Obstetrician & Gynaecologist Infertility Specialist.
Cervical Cancer DR KHALID H. WALI SAIT (FRCSC) ASSOCIATE PROFESSOR OF GYNECOLOGICAL ONCOLOGY King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
Updates on Pap Smear Guidelines 2014
Carcinoma of the Vulva.
M. Munjoma. Outline Burden of HPV Disease HPV in Zimbabwe HPV Lab Development HPV Protocols.
Spotlight on Cervical Cancer Screening
Malignant lesion of the Vulva
Female Genital Tract 1-Vulva 2-Vagina 3-Cervix 4-Uterine corpus
Cervical Cancer Source: SEER’s Training Web Site
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
HPV Vaccine – Does it Prevent Cervical Cancer?
 The term post menopause is applied to women who have not experienced a menstrual bleed for a minimum of 12 months, assuming that they do still have.
Vulvar and Vaginal lesions
Vulvar Cancer A. Gari MD..
CANCER CERVIX A PREVENTABLE CANCER Dr NEETA DHABHAI Sr Consultant. – Gynaecologist Member Expert - Indian Cancer Winners’ Association
Options for surgical trials in vulva cancer.
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Cervical Sample Taker Training 2015 THE NHS CERVICAL SCREENING PROGRAMME (NHSCSP)
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Cancer Cx. Que-1 The most common gynecological malignancy in the world is – a) Vaginal Ca b) Cervical Ca c) Uterine Ca d) Ovarian Ca.
Adult Medical-Surgical Nursing
2012 European guideline for the management of anogenital warts C.J.N. Lacey,†,* S.C. Woodhall,† A. Wikstrom,‡ J. Ross§ †Hull York Medical School, University.
Premalignant lesions of the cervix. Applied anatomy.
1www.zohrehyousefi.com. 2 Major risk factors: smoking immunosuppression organ transplantation HIV infectionCigarette smoking, nutritional deficiency,
VULVA.
HPV and Pap Guidelines Jennifer Johnson MD. Objectives 1. Define the new PAP guidelines. 2. Identify the historical trends and new evidence resulting.
HPV AND WOMEN’S CANCER A.C. Evans. M.D., Ph.D.. HPV and Women’s Cancer I have no relevant financial relationships with the manufacturer(s) of any commercial.
HPV-related anogenital cancers
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
HIV & HPV Co-infections: Clinical Presentation & Management
Carcinoma Vulva & Vagina
Anal Intra-epithelial Neoplasia A report of 2 cases Philipp Narciso, M.D. UAMS-AHEC South Arkansas.
Management of Vulvar Cancer
ELIGIBILITY CRITERIA- Summarised
Trreatment of Preinvasive Lesions
Please go to: polleverywhere
VULVAR İNTRAEPİTELYAL NEOPLAZİLERDE YAKLAŞIM
Lichen sclerosus and Lichen planus and risk for malignancy
Indications for Breast MR Imaging
Department of Gynaecology and Obstetrics
Cervical Cancer in California
Cervical Cancer Colposcopy & Treatment
Update of the management of
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Dr N Shailaja Dr Pradeep
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
F.Behnamfar Gynecology Oncology Fellow Professor
QUIZ QUESTIONS 1) WHAT ARE THE TWO TYPES OF CERVICAL CANCER?
From Abacus to Electronic Repository …..and HPV, CIN along the way
Nat. Rev. Clin. Oncol. doi: /nrclinonc
SBÜ KAYSERİ ERH Doç. Dr. Gökhan Açmaz
Management of endometrial cancer found on routine hysterectomy for benign disease Prof Dr M Anıl Onan MAY ANTALYA.
AGC&AIS Setareh Akhavan M.D Gynecologist Oncologist
Human Papillomavirus (HPV) in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical excisional treatment of young women: A population-based study
Volume 121, Issue 1, Pages (April 2011)
SH-sheikhhasani Gyn-oncologist
Diagnosis & Management Of VAIN/VIN
Downgrading -IN 2, Diagnoses and Predicting Higher-grade Lesions
Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.
Presentation transcript:

MULTIFOCAL HPV DISEASE IMIQUIMOD AN ALTERNATIVE THERAPY Vitorino A, Ferreira S, Pinto Vieira L, Nabais H Fundação D. Anna Sommer Champalimaud Dr. Carlos Montez Champalimaud Champalimaud Centre for the Unknown MULTIDISCIPLINAR UNIT OF GYNECOLOGY ABSTRACT HPV Multicentric lower genital tract disease is well documented. A High percentage of women with vulvar intraepetilial neoplasia (VIN) have associated cervical, vaginal and/or anal lesions. The standard treatment of VIN 3 lesions (Squamous intraepithelial lesion High grade Vulvar) has been surgical excision or vulvectomy, witch is associated with physical and psychosexual morbidity and high recurrence rate. Recent studies show the use of the immune response modifier imiquimod as an alternative or adjunct to surgery to extensive multifocal disease with better results in the preservation of the anatomy and function of the vulva and lower morbility. The recurrence rates is lower, average 35% of the patients as a complete response but the studies demonstrate that 9% of complete imiquimod responders developed a recurrence . Therefore, careful long-term surveillance is mandatory. RESULTS Treatment was initiated with 5% imiquimod cream three times a week during 3 Months, without important adverse events. The patient stopped smoking. At 12, 18 and 24 weeks the patient was asymptomatic; negative vulvoscopy;. keeps tight follow-up . CONCLUSION Imiquimod can be an effective and well tolerated treatment for high grade VIN. These lesions are often multifocal and the recurrence rate is high, thus the need for prolonged follow-up of the entire lower genital tract. It is also important to motivate the patient to change lifestyle habits. CLINICAL CASE 66 years, female; smoker; Previous history of total hysterectomy and bilateral anexectomy after conization for CIN 3 with positive margins. Unattended for two years. High Grade Vaginal Intraepithelial neoplasia was documented after positive Cytology and HPV 16. It was not possible to rule out invasion. A partial vaginectomy confirmed the diagnosis and excluded invasion. Albeit consecutive negative Cytologies every 6 months, she had a vulvoscopy with biopsy for persistent vulvar itching. VIN 3 was documented (multifocal lesions) and persistence of HPV 16. Anal cytology was negative and Pelvic MRI showed no evidence of invasive lesions. OBJECTIVES Assess the efficacy of imiquimod in multifocal High Grade Vulvar Intraepithelial Neoplasia (VIN). Stress the need for careful evaluation and follow-up after the diagnosis/treatment of High Grade Cervical Intraepithelial Neoplasia. REFERENCES: Annelinde Terlou, Manon Van Seters, Patricia C. Ewing, Neil K. Aaronson ”Treatment of vulvar intraepithelial neoplasia with topical imiquimod” Peter Hillemanns, Xiuli Wang, Stefanie Staehle, Wolfgang Michels, Chirsian Dannecker “Evaluation of different tratment modalities for vulvar intraepithelial neoplasia (VIN); Christios Lavazzo, EleniPitsouni, Stavros Athanasiou Matthew E. Falagas Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia.